WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that:
* J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the “ThinkClinic” educational forum for healthcare investors sponsored by ThinkEquity Partners LLC at The Pierre in New York City at 2:35 p.m. Eastern Daylight Time on October 4, 2007;
